Imatinib Glenmark (Imatinib)

Imatinib blocks the ATP‑binding sites of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases, locking them in an inactive state. This stops downstream signalling that normally promotes proliferation and survival of cancer cells, leading to reduced tumour growth and, in many patients, disease remission.

The dose of Imatinib Glenmark is individualized by the prescribing clinician based on the specific indication, disease stage, patient weight, renal and hepatic function, and any concomitant therapies. Only a qualified health‑care professional should determine the appropriate regimen.

Safety data for Imatinib in pregnancy and lactation are limited. The drug is generally not recommended for use in pregnant or nursing women unless the potential benefit justifies the potential risk. Patients should discuss family planning and breastfeeding considerations with their physician.

To place an order, submit an enquiry on the Imatinib Glenmark product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Imatinib was the first BCR‑ABL inhibitor and remains a standard first‑line option for CML and Ph+ ALL. Newer agents such as dasatinib or nilotinib may offer faster molecular responses but can have different safety profiles and drug‑interaction potentials. Choice of therapy depends on disease characteristics, patient comorbidities and physician judgment.

Imatinib Glenmark should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in humid environments such as bathrooms.

The medication is taken orally, usually with a glass of water. It can be taken with or without food, but patients should follow any specific instructions from their prescriber. Swallow tablets whole; do not crush or chew unless directed by a health‑care professional.

Serious adverse events include hepatotoxicity, severe neutropenia, cardiac failure, pulmonary hypertension and rare but severe skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored regularly for liver enzymes, blood counts and cardiac function, and any alarming symptoms should be reported promptly.

Imatinib Glenmark is contraindicated in individuals with known hypersensitivity to imatinib or any of its excipients. Patients with severe hepatic impairment, uncontrolled cardiac disease, or those receiving certain strong CYP3A4 inhibitors should avoid use unless a specialist determines that benefits outweigh risks.